Pandemics and Alertness Co-leader WG2 (Fighting the virus), LINXS Fellow

Dept. of Immunotecnology & SciLifeLab Drug Discovery and Development Platform, Lund University, Lund, Sweden

Prof. Mats Ohlin defended his thesis in Immunotechnology at Lund University with a specific focus on human antibody repertoires in 1992. He has been engaged in antibody technology development and studies of immune responses throughout his career, with a specific focus of immune responses associated to allergic disease. He also developed a scaffold for development of carbohydrate-specific probes, and exploited X-ray and neutron crystal structure determination in this context. He was appointed Assoc. Prof of Immunotechnology in 1995 and Professor of Immunotechnology in 2003. He was appointed Platform Scientific Director of the Human Antibody Therapeutics unit (now Display and Selection Technology) of the national infrastructure Science for Life Laboratory (SciLifeLab) Drug Discovery and Development Platform in 2016 when the laboratory in Lund was introduced into this national infrastructure for therapeutic drug development. He has since 2021 acted as Co-chair of the Inferred Allele Review Committee of The Adaptive Immune Receptor Repertoire Community (AIRR-C) of the Antibody society (https://www.antibodysociety.org/), a committee with responsibility to judge the validity of germline immunoglobulin and TCR genes inferred from AIRR-Seq and genomic data. This committee directly collaborates with the International Union of Immunological Societies’ T-cell Receptor and Immunoglobulin Nomenclature Review Committee on aspects of gene and allele nomenclature.